SMC Arthritis Forum/Dr.Hanady Manasfi on X: Comparison #BASDAI and #ASDAS #spondyloarthtopathy #EULAR2020 / X
Descrição
PDF) Spondyloarthritis: is it time to replace BASDAI with ASDAS?
Efficacy of Upadacitinib in Patients with Non-Radiographic Axial
Comparison of Composite Indices for Disease Activity in Patients
Comparison of Established and New, Preliminarily Proposed ASAS Cut
Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in
Reviewing Disease Activity Indices in Spondyloarthritis From the
Use of Imaging in Axial Spondyloarthritis for Diagnosis and
ASDAS high disease activity versus BASDAI elevation in patients
Frontiers Juvenile Spondyloarthritis: What More Do We Know About
Evaluation of spondylarthritis activity by patients and physicians
Axial Spondyloarthritis RINVOQ® (upadacitinib)
de
por adulto (o preço varia de acordo com o tamanho do grupo)
